Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enbridge Inc (ENB) vs Novartis AG (NVS) Price & Performance

Enbridge IncTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Enbridge Inc vs Novartis AG — how do they compare? Enbridge Inc trades at $51.76 (market cap $112.62B), while Novartis AG trades at $153.05 (market cap $295.37B). The key difference: Novartis AG is far larger — about 2.6× Enbridge Inc's market cap, and Enbridge Inc pays the higher dividend (5.34%). Which is the better fit depends on your goals.

ENBNVS
Market Cap
$112.62B$295.37B
Sector
EnergyHealth
52-Week High
$58.04$168.62
52-Week Low
$45.23$119.31
Enterprise Value
$196.53B$336.69B
Dividend Yield
5.34%3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enbridge Inc

Enbridge (ENB) trades at $51.39, up 0.21% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $65.2B revenue, 11.5% net margin, and consistent dividend growth spanning 31 years. Recent Q2 2026 results exceeded expectations with $0.46 EPS versus $0.43 estimate, supported by robust pipeline and utility performance. Analyst sentiment is balanced with 48% buy ratings while technical indicators show oversold conditions with RSI at 14.8.

ENB presents a compelling income opportunity with 5.3% dividend yield and $41B growth pipeline, though faces regulatory risks from Line 5 litigation and Wisconsin tribal land dispute. The stock's current valuation at 27.8x P/E appears reasonable given stable cash flows, but investors should monitor debt levels approaching 49% of assets and potential project delays affecting growth execution.

Novartis AG

Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.

The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enbridge Inc

Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.

Read more on ENB

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS